Catapult Award Project Details
Dr. Ranjit Bindra at Yale University studies pediatric glioma, an aggressive type of brain cancer that has a 5-year survival rate of less than 25 percent. Dr. Bindra is testing a novel drug in pediatric patients with a specific subtype of glioma (IDH1/2 mutant). Because of the inability of cells to perform efficient DNA repair in gliomas where IDH1/2 is mutated, these gliomas are sensitive to inhibition of the PARP protein. PARP is involved in repair of DNA damage and its inhibition makes the cancer more sensitive to standard therapies, lowering the dosage needed when used in combination. Thus, long-term toxicity can be reduced. Dr. Bindra’s cutting-edge study can significantly improve long-term survival rates and reduce toxicity in pediatric glioma patients and lead to a potential shift in treatment standards.
Dr. Bindra, will partner with the Pacific Neuro-Oncology Consortium (PNOC) to administer the clinical trial at 18 pediatric cancer centers in the U.S., enrolling 78 patients. The study is proposed to take 3 years to complete. Dr. Bindra will also collaborate with Teen Cancer America, an advocacy group dedicated to AYA patient survivorship, to share the study’s results. Early in May of 2019, Dr. Bindra enrolled the first patient onto his trial through the PNOC clinical site at the University of California, San Francisco.
This program is supported in part by generous contributions from the Kiewit Corporation.